- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05037760
Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis
March 2, 2022 updated by: Keros Therapeutics, Inc.
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis
This is a Phase 2, multicenter, open-label study to evaluate the safety and efficacy of KER-050 as monotherapy or in combination with ruxolitinib in participants with Myelofibrosis.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
KER-050 is an investigational therapeutic protein designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins to promote hematopoiesis.
It is being developed for the treatment of low blood cell counts, or cytopenias including anemia and thrombocytopenia in patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF)
Study Type
Interventional
Enrollment (Anticipated)
110
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rachael Ryzman
- Phone Number: 603-548-3907
- Email: KER050-MF-301@kerostx.com
Study Locations
-
-
New South Wales
-
Tweed Heads, New South Wales, Australia, 2485
- Recruiting
- The Tweed Hospital
-
-
South Australia
-
Woodville South, South Australia, Australia, 5042
- Recruiting
- Flinders Medical Centre
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3355
- Recruiting
- St. Vincent's Hospital Melbourne
-
Melbourne, Victoria, Australia, 3050
- Recruiting
- Royal Melbourne Hospital
-
Wendouree, Victoria, Australia, 3355
- Recruiting
- Ballarat Oncology & Hematology Service
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Male or female ≥18 years of age, at the time of signing informed consent.
- Diagnosis of PMF, post-PV MF, or post-ET MF according to the 2017 World Health Organization criteria.
Arm-specific criteria:
Arm 1A:
- Previously treated with JAK inhibitor(s) or Participant is ineligible for JAK inhibitor(s)
- Anemia, defined as hemoglobin ≤10 g/dL during screening, or receiving RBC transfusions
Arm 2A:
- Previously treated with JAK inhibitor(s) or Participant is ineligible for JAK inhibitor(s)
- Anemia, defined as hemoglobin ≤10 g/dL during screening, or receiving RBC transfusions
Arm-specific criteria for 1B and 2B:
- Has been receiving ruxolitinib for ≥8 weeks prior to C1D1 and on a stable dose for ≥4 weeks prior to C1D1.
- Anemia, defined as hemoglobin ≤10 g/dL during screening, or receiving RBC transfusions
Key Exclusion Criteria:
Presence of the following cardiac conditions:
- New York Heart Association Class 3 or 4 heart failure
- QTcF >500 msec on the screening or C1D1 electrocardiogram (ECG)
- Uncontrolled clinically significant arrhythmia (participants with rate-controlled atrial fibrillation are not excluded)
- Acute myocardial infarction or unstable angina pectoris <6 months prior to C1D1
- History of stroke, deep venous thrombosis, or arterial embolism within 6 months prior to C1D1.
- Any malignancy other than PMF, post-ET MF, or post-PV MF that has not been in remission and/or has required systemic therapy including radiation, chemotherapy, hormonal therapy, or surgery, within 1 year prior to C1D1. In-situ cancers, squamous cell, and basal cell carcinomas which have been fully excised, and monoclonal gammopathy of unclear significance are allowed at the discretion of the Investigator.
- History of solid organ or hematological transplantation.
- Presence of uncontrolled hypertension, defined as systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg despite adequate treatment.
- Diagnosis of hemolytic anemia, active bleeding, hemoglobinopathies, or congenital disorders as a cause of the participant's anemia.
- CTCAE Grade ≥2 bleeding events within the 3 months prior to C1D1.
- Bone marrow blast percentage >2%. Participants with blast % between 2-5% are allowed if at least 2 bone marrows >6 months apart demonstrate stability of blast percentage, these participants must be reviewed with the Medical Monitor prior to study entry.
- Prior treatment with luspatercept, sotatercept, or other commercially available or investigational TGF-β inhibitors (all Arms)
Treatment within 28 days prior to C1D1 with:
- Erythropoiesis stimulating agent (ESA)
- Granulocyte colony-stimulating factor (G-CSF)
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- Thrombopoietin agonists (TPO)
- Immunomodulator imide drugs (IMiDs; e.g., thalidomide, pomalidomide, lenalidomide)
- Interferon
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1a
Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) monotherapy
|
KER-050 administered (SC) for up to 13 cycles
|
EXPERIMENTAL: Arm 1b
Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
|
KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib
|
EXPERIMENTAL: Arm 2a
Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) monotherapy
|
KER-050 administered (SC) for up to 13 cycles
|
EXPERIMENTAL: Arm 2b
Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
|
KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (Safety and Tolerability)
Time Frame: 64 Weeks
|
Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs)
|
64 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subgroup of transfusion-independent participants
Time Frame: 24 weeks
|
|
24 weeks
|
Subgroup of participants with anemia requiring red blood cell (RBC) transfusions
Time Frame: 24 weeks
|
|
24 weeks
|
Proportion of participants with decrease in spleen volume of ≥35% from baseline as measured by computed tomography (CT) (excluding participants status post splenectomy or splenic irradiation)
Time Frame: At Week 24 and at Week 52
|
At Week 24 and at Week 52
|
|
Proportion of participants with improvement in the Myelofibrosis Symptom Assessment Form Total Symptom Score (MF-SAF-TSS) of ≥50% from baseline
Time Frame: At Week 24 and at Week 52
|
At Week 24 and at Week 52
|
|
Proportion of participants with progression to AML (bone marrow blasts >20%)
Time Frame: At Week 24 and at Week 52
|
At Week 24 and at Week 52
|
|
Proportion of participants with progression to accelerated MF (bone marrow blasts ≥10%)
Time Frame: At Week 24 and at Week 52
|
At Week 24 and at Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 16, 2021
Primary Completion (ANTICIPATED)
April 1, 2025
Study Completion (ANTICIPATED)
June 1, 2025
Study Registration Dates
First Submitted
August 23, 2021
First Submitted That Met QC Criteria
September 1, 2021
First Posted (ACTUAL)
September 8, 2021
Study Record Updates
Last Update Posted (ACTUAL)
March 17, 2022
Last Update Submitted That Met QC Criteria
March 2, 2022
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KER050-MF-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelofibrosis
-
Assaf-Harofeh Medical CenterUnknownMyelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ETIsrael
-
Centre Hospitalier Annecy GenevoisCompleted
-
AbbVieRecruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
-
AbbVieTerminatedMyelofibrosis (MF)United States, Korea, Republic of, South Africa
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingModerate and High Risk MyelofibrosisChina
-
Telios Pharma, Inc.RecruitingPrimary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET MyelofibrosisSpain, United States, France, Poland, Italy, Germany
Clinical Trials on KER-050 monotherapy
-
Keros Therapeutics, Inc.RecruitingMyelodysplastic Syndromes | CytopeniaAustralia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
-
Keros Therapeutics, Inc.RecruitingPulmonary Arterial HypertensionUnited States, Australia
-
Pieris Pharmaceuticals GmbHFGK Clinical Research GmbHCompleted
-
Keros Therapeutics, Inc.RecruitingIron Deficiency AnemiaAustralia, Israel, Romania
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.Not yet recruiting
-
Xizang Haisco Pharmaceutical Co., LtdRecruiting
-
Masonic Cancer Center, University of MinnesotaActive, not recruiting
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
Peking Union Medical College HospitalCompletedChronic Periaortitis | Tocilizumab MonotherapyChina
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of